STOCK TITAN
  1. Home
  2. News
  3. ABBV

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

News
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
Rhea-AI Summary
Richard A. Gonzalez will retire as AbbVie CEO on July 1, 2024, with Robert A. Michael succeeding him. The transition was announced by AbbVie's board of directors, highlighting Michael's leadership capabilities and strategic vision. Gonzalez will become Executive Chairman, ensuring a seamless CEO succession plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
management
-
News
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
Rhea-AI Summary
AbbVie (ABBV) announces 17 accepted abstracts for ECCO 2024, showcasing data on IBD treatments. Key presentations include comparisons of risankizumab and ustekinumab in Crohn's disease, risankizumab maintenance therapy in ulcerative colitis, and long-term safety data on upadacitinib in Crohn's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AbbVie Declares Quarterly Dividend
Rhea-AI Summary
AbbVie Inc. declares a quarterly cash dividend of $1.55 per share, payable on May 15, 2024, to stockholders of record on April 15, 2024. The company has increased its dividend by over 285% since its inception in 2013 and is part of the S&P Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
dividends
News
AbbVie Completes Acquisition of ImmunoGen
Rhea-AI Summary
AbbVie completes acquisition of ImmunoGen, adding ELAHERE, a transformative treatment for ovarian cancer, to its portfolio. The acquisition expands AbbVie's oncology pipeline, reaffirms 2024 EPS guidance, and positions the company for long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
acquisition
-
News
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases
Rhea-AI Summary
AbbVie has expanded its collaboration with Calibr-Skaggs to further explore the switchable CAR-T (sCAR-T) platform in solid tumor indications and autoimmune diseases. The innovative approach may offer enhanced control and precision for activating CAR-Ts, potentially reducing adverse effects of existing CAR-T cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
News
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Rhea-AI Summary
AbbVie (ABBV) reported a decrease in full-year diluted EPS of 59.0% on a GAAP basis and 19.3% on an adjusted basis. The company delivered full-year net revenues of $54.318 billion, with decreases in global net revenues from various portfolios. Fourth-quarter net revenues were $14.301 billion, with decreases in global net revenues from the immunology, oncology, and aesthetics portfolios. AbbVie announced definitive transaction agreements to acquire ImmunoGen and Cerevel Therapeutics, providing 2024 adjusted diluted EPS guidance range of $11.05 to $11.25. The company also reaffirmed expectations for a high single-digit compound annual revenue growth rate through 2029.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
earnings
News
Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-Expression
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, released the 'Decoding the Future of Aesthetic Individuality' report, focusing on understanding the evolving consumer mix and their aesthetic needs. The report highlights the importance of individuality in aesthetics and the need for personalized approaches to consultation and treatment. It also emphasizes the role of social media in shaping beauty standards and the impact of individuality on defining beauty. The research includes insights from leading global experts and extensive research across consumer and business media, global social listening data, and market and industry reports from multiple geographies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
News
Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024
Rhea-AI Summary
Allergan Aesthetics, a global leader in aesthetics, will be showcasing its commitment to Individuality, Innovation, and Integrity at the IMCAS World Congress 2024. The event will feature a symposium, live injection session, Meet the Expert presentations, and an interactive exhibition booth, all centered around the theme 'True Originals'. The company will also present new clinical data to support its evolving aesthetics portfolio. The AMI symposium will focus on the impact of delivering individualized aesthetic results through real-world examples, with a live injection session from the Allergan Center of Excellence in Italy. The event will also mark the preview of the 'Moving the Needle on Ethics' book, a compilation of thought-provoking pieces on ethical topics associated with aesthetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News
Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, has announced the results of a consumer survey for its loyalty rewards program, Allē, showing a ninety-two percent satisfaction rate among members treated in the past twelve months. Allē aims to educate consumers and solidify its position as the leading aesthetics loyalty rewards program in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
News
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
Rhea-AI Summary
AbbVie (ABBV) launches PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease. The subcutaneous 24-hour infusion of levodopa-based therapy demonstrated sustained improvements in 'Off' time, 'On' time without dyskinesia, and morning akinesia. Parkinson's disease affects approximately 6.1 million people globally and is expected to double by 2040. PRODUODOPA provides continuous delivery of levodopa, extending the period when symptoms are well-controlled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
Stock ABBV logo
Abbvie Inc

NYSE:ABBV

ABBV Rankings

#29 Ranked by Market Cap
#2312 Ranked by Stock Gains
#930 Ranked by Dividends

ABBV Stock Data

287.80B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.